Vertex will acquire Crinetics for $10B in cash, adding best-in-class endocrinology assets with ~$5B peak sales potential. The deal accelerates revenue growth, enhances long-term earnings, and strengthens the specialty endocrinology portfolio.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.